AZN vs. QBR-B.TO
AZN (AstraZeneca PLC) and QBR-B.TO (Quebecor Inc) are both stocks. AZN operates in Drug Manufacturers - General (Healthcare), while QBR-B.TO operates in Telecom Services (Communication Services). Over the past 10 years, AZN returned 15.97%/yr vs 15.77%/yr for QBR-B.TO. At a 0.15 correlation, their price movements are largely independent.
Performance
AZN vs. QBR-B.TO - Performance Comparison
Loading charts...
Different Trading Currencies
AZN is traded in USD, while QBR-B.TO is traded in CAD. To make them comparable, the QBR-B.TO values have been converted to USD using the latest available exchange rates.
Returns By Period
In the year-to-date period, AZN achieves a 1.85% return, which is significantly lower than QBR-B.TO's 30.80% return. Both investments have delivered pretty close results over the past 10 years, with AZN having a 15.97% annualized return and QBR-B.TO not far behind at 15.77%.
AZN
- 1D
- 1.04%
- 1M
- 0.32%
- YTD
- 1.85%
- 6M
- 4.25%
- 1Y
- 29.14%
- 3Y*
- 9.91%
- 5Y*
- 11.83%
- 10Y*
- 15.97%
QBR-B.TO
- 1D
- 0.49%
- 1M
- 17.93%
- YTD
- 30.80%
- 6M
- 35.04%
- 1Y
- 76.26%
- 3Y*
- 30.47%
- 5Y*
- 17.11%
- 10Y*
- 15.77%
AZN vs. QBR-B.TO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
AZN AstraZeneca PLC | 1.85% | 43.30% | -0.62% | 1.44% | 19.14% | 19.66% | 3.12% | 35.68% | 13.86% | 33.10% |
QBR-B.TO Quebecor Inc | 30.80% | 77.98% | -3.97% | 11.08% | 3.73% | -9.70% | 3.88% | 21.76% | 12.69% | 37.37% |
Correlation
The correlation between AZN and QBR-B.TO is 0.00, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.00 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.09 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.10 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.13 |
Correlation (All Time) Calculated using the full available price history since Jul 7, 2006 | 0.15 |
The correlation between AZN and QBR-B.TO shifts across timeframes, from 0.00 (1 year) to 0.15 (all time), reflecting how their relationship changes across market environments.
Fundamentals
AZN:
$286.33B
QBR-B.TO:
CA$15.74B
AZN:
$6.66
QBR-B.TO:
CA$3.85
AZN:
27.56
QBR-B.TO:
17.68
AZN:
0.04
QBR-B.TO:
1.48
AZN:
4.74
QBR-B.TO:
2.75
AZN:
6.05
QBR-B.TO:
5.88
AZN:
$60.44B
QBR-B.TO:
CA$5.73B
AZN:
$49.37B
QBR-B.TO:
CA$2.22B
AZN:
$20.47B
QBR-B.TO:
CA$2.40B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
AZN vs. QBR-B.TO — Risk / Return Rank
AZN
QBR-B.TO
AZN vs. QBR-B.TO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for AstraZeneca PLC (AZN) and Quebecor Inc (QBR-B.TO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| AZN | QBR-B.TO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.00 | ||
| Sortino ratioReturn per unit of downside risk | -2.20 | ||
| Omega ratioGain probability vs. loss probability | 1.22 | 1.53 | -0.31 |
| Calmar ratioReturn relative to maximum drawdown | 1.91 | 6.39 | -4.48 |
| Martin ratioReturn relative to average drawdown | 5.05 | 21.66 | -16.61 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| AZN | QBR-B.TO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.15 | 3.15 | -2.00 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.50 | 0.76 | -0.26 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.64 | 0.72 | -0.08 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.50 | 0.53 | -0.03 |
Drawdowns
AZN vs. QBR-B.TO - Drawdown Comparison
The maximum AZN drawdown since its inception was -48.94%, smaller than the maximum QBR-B.TO drawdown of -74.00%. Use the drawdown chart below to compare losses from any high point for AZN and QBR-B.TO.
Loading charts...
Drawdown Indicators
| AZN | QBR-B.TO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -48.94% | -74.00% | +25.06% |
Max Drawdown (1Y)Largest decline over 1 year | -15.43% | -12.00% | -3.43% |
Max Drawdown (3Y)Largest decline over 3 years | -27.87% | -21.14% | -6.73% |
Max Drawdown (5Y)Largest decline over 5 years | -27.87% | -32.29% | +4.42% |
Max Drawdown (10Y)Largest decline over 10 years | -27.87% | -36.76% | +8.89% |
Current DrawdownCurrent decline from peak | -12.00% | -3.78% | -8.22% |
Average DrawdownAverage peak-to-trough decline | -11.37% | -12.80% | +1.43% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.80% | 3.53% | +2.27% |
Volatility
AZN vs. QBR-B.TO - Volatility Comparison
The current volatility for AstraZeneca PLC (AZN) is 7.49%, while Quebecor Inc (QBR-B.TO) has a volatility of 10.45%. This indicates that AZN experiences smaller price fluctuations and is considered to be less risky than QBR-B.TO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| AZN | QBR-B.TO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.49% | 10.45% | -2.96% |
Volatility (6M)Calculated over the trailing 6-month period | 17.47% | 18.04% | -0.57% |
Volatility (1Y)Calculated over the trailing 1-year period | 25.51% | 24.34% | +1.17% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 24.00% | 22.62% | +1.38% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 24.91% | 21.94% | +2.97% |
Dividends
AZN vs. QBR-B.TO - Dividend Comparison
AZN's dividend yield for the trailing twelve months is around 2.90%, more than QBR-B.TO's 2.20% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AZN AstraZeneca PLC | 2.90% | 1.70% | 2.27% | 2.15% | 2.12% | 2.35% | 2.80% | 2.81% | 3.69% | 3.95% | 5.01% | 4.06% |
QBR-B.TO Quebecor Inc | 2.20% | 2.71% | 4.13% | 3.81% | 3.97% | 3.85% | 2.44% | 1.18% | 0.67% | 0.77% | 0.91% | 0.77% |
Financials
AZN vs. QBR-B.TO - Financials Comparison
This section allows you to compare key financial metrics between AstraZeneca PLC and Quebecor Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
AZN vs. QBR-B.TO - Profitability Comparison
AZN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a gross profit of 12.61B and revenue of 15.29B. Therefore, the gross margin over that period was 82.5%.
QBR-B.TO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Quebecor Inc reported a gross profit of 608.10M and revenue of 1.40B. Therefore, the gross margin over that period was 43.6%.
AZN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported an operating income of 4.25B and revenue of 15.29B, resulting in an operating margin of 27.8%.
QBR-B.TO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Quebecor Inc reported an operating income of 367.20M and revenue of 1.40B, resulting in an operating margin of 26.3%.
AZN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a net income of 3.08B and revenue of 15.29B, resulting in a net margin of 20.2%.
QBR-B.TO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Quebecor Inc reported a net income of 225.40M and revenue of 1.40B, resulting in a net margin of 16.2%.
Frequently Asked Questions
AZN and QBR-B.TO have a correlation of 0.00, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for AZN and QBR-B.TO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer